
    
      Patients will be randomised to:

      Arm A: PLD 30 mg/m2 and carboplatin AUC 5; Arm B: PLD 30 mg/m2 and trabectedin 1.1 mg/m2.
      Patients' characteristics: patients over 18 years of age with advanced, progressive ovarian
      cancer 6-12 months after completion of first line or second line treatment with
      platinum-based chemotherapy.
    
  